secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2024-04-08T23:59:59+00:00
Accession:  0001193125-24-089654
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres Therapeutics shareholders approve increase in authorized common shares from 240M to 360M
--------------------------------------------------------------------------------

- Amendment to certificate of incorporation filed April 5, 2024, increasing authorized shares from 240M to 360M.
- Shareholder vote: 81.5M for, 21.3M against, 1.5M abstain (Item 4).
- Two Class III directors elected: Paul R. Biondi (53.5M for) and Kurt C. Graves (51.1M for).
- Ratification of PwC as auditor approved (100.8M for).
- Advisory say-on-pay and simple majority stockholder proposal both passed (non-binding).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312524089654/0001193125-24-089654-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312524089654/d798362d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-089654

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer